CN105902630A - 一种治疗鼻炎的药物组合物及其制备方法 - Google Patents
一种治疗鼻炎的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN105902630A CN105902630A CN201610402881.9A CN201610402881A CN105902630A CN 105902630 A CN105902630 A CN 105902630A CN 201610402881 A CN201610402881 A CN 201610402881A CN 105902630 A CN105902630 A CN 105902630A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- herba
- fine powder
- standby
- aspongopus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 241000660877 Coridius Species 0.000 claims abstract description 35
- 241000242759 Actiniaria Species 0.000 claims abstract description 34
- 241000628997 Flos Species 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000002791 soaking Methods 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 61
- 239000012141 concentrate Substances 0.000 claims description 39
- 239000000706 filtrate Substances 0.000 claims description 39
- 241000282898 Sus scrofa Species 0.000 claims description 34
- 210000003608 fece Anatomy 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 29
- 238000001035 drying Methods 0.000 claims description 26
- 238000009835 boiling Methods 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 238000002386 leaching Methods 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 2
- 239000004575 stone Substances 0.000 claims 2
- 241000331528 Chlorophytum capense Species 0.000 claims 1
- 241000233855 Orchidaceae Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 235000014043 Glechoma hederacea var parviflora Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000233044 Lysionotus Species 0.000 abstract 1
- 244000215554 Nepeta hederacea Species 0.000 abstract 1
- 241001373813 Saussurea japonica Species 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 8
- 238000002156 mixing Methods 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000561734 Celosia cristata Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000009151 chronic rhinitis Diseases 0.000 description 2
- 210000001520 comb Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical group [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/264—Aristolochia (Dutchman's pipe)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Insects & Arthropods (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种治疗鼻炎的药物组合物及其制备方法,该药物组合物由以下重量份的药物制成:风毛菊、黑冰片、九香虫、石吊兰、白芷、两头尖、连钱草、细辛、鸡冠花、甘草,通过水煎煮、醇浸泡工艺制成,本发明治疗鼻炎270例,总有效率达94.82%,效果明显,并且未发现不良反应与毒副作用,说明本发明药物组合物治疗鼻炎疗效显著,具有良好推广价值。
Description
技术领域
本发明涉及医药发明领域,具体涉及一种治疗鼻炎的药物组合物及其制备方法。
背景技术
鼻炎指的是鼻腔粘膜和粘膜下组织的炎症。表现为充血或者水肿,患者经常会出现鼻塞,流清水涕,鼻痒,喉部不适,咳嗽等症状。临床的各种鼻炎:急性鼻炎、慢性鼻炎(慢性单纯性鼻炎、慢性肥厚性鼻炎、慢性干燥性鼻炎)、过敏性鼻炎(季节性鼻炎、常年性鼻炎)、干燥性鼻炎、萎缩性鼻炎、干酪性鼻炎、药物性鼻炎、血管运动性鼻炎、嗜酸细胞增多性非***反应性鼻炎、过强反射性鼻炎等。目前治疗鼻炎的药物虽然多,但基本只能治标不治本,因此急需要一种能根治鼻炎的药物。
本发明人为了解决上述问题,研发了一种新药。
发明内容
本发明的目的是提供一种治疗鼻炎的药物组合物。
本发明的另一目的是提供一种治疗鼻炎的药物组合物制备方法。
本发明提供一种治疗鼻炎的药物组合物,该药物组合物由以下重量份的药物制成:风毛菊20-70份、黑冰片5-30份、九香虫10-60份、石吊兰10-60份、白芷10-60份、两头尖20-65份、连钱草15-65份、细辛5-40份、鸡冠花10-60份、甘草10-60份。
优选的,本发明所述的药物组合物由以下重量份的药物制成:风毛菊25-65份、黑冰片8-28份、九香虫15-55份、石吊兰15-55份、白芷15-55份、两头尖25-60份、连钱草20-60份、细辛10-30份、鸡冠花15-55份、甘草15-55份。
进一步优选的,本发明所述的药物组合物由以下重量份的药物制成:风毛菊30-60份、黑冰片10-25份、九香虫20-50份、石吊兰20-50份、白芷20-50份、两头尖30-50份、连钱草30-50份、细辛15-25份、鸡冠花20-50份、甘草20-50份。
更进一步优选的,本发明所述的药物组合物由以下重量份的药物制成:风毛菊35-55份、黑冰片12-22份、九香虫25-45份、石吊兰25-45份、白芷25-45份、两头尖35-45份、连钱草35-45份、细辛17-22份、鸡冠花25-45份、甘草25-45份。
更进一步优选的,本发明所述的药物组合物由以下重量份的药物制成:风毛菊40份、黑冰片20份、九香虫35份、石吊兰35份、白芷35份、两头尖40份、连钱草40份、细辛20份、鸡冠花35份、甘草35份。
本发明所述的药物组合物还含有药学上可接受的载体或稀释剂。
本发明所述药物组合物为固体制剂或液体制剂,所述固体制剂为片剂、胶囊剂、颗粒剂或丸剂;所述液体制剂为口服液。
本发明所述的药物组合物的制备方法包括以下步骤:
将风毛菊、黑冰片、九香虫、石吊兰、白芷、两头尖、连钱草、细辛、鸡冠花、甘草粉碎过筛,与药学上可接受的载体或稀释剂混合均匀,制备成制剂。
本发明所述的药物组合物的制备方法包括以下步骤:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮3-6次,每次2-4小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入2-4倍量的75-90%的乙醇,浸泡13-18小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加4-6倍量的水,煎煮3-5次,每次0.5-2小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入药学上可接受的载体或稀释剂混合均匀,制成制剂。
优选的,本发明所述的药物组合物的制备方法包括以下步骤:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮5次,每次3小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入3倍量的75%的乙醇,浸泡15小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加5倍量的水,煎煮4次,每次1小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入药学上可接受的载体或稀释剂混合均匀,制成制剂。
所述重量份数可以是μg、mg、g、kg等医药领域公知的重量单位。
倍量的含义是指药材的重量比。
所述药学上可接受的载体或稀释剂是指药学领域常规的药物载体,选自填充剂、粘合剂、崩解剂、润滑剂、表面活性剂或矫味剂中的一种或几种。
其中所述填充剂选自淀粉、蔗糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素或葡萄糖等;
所述粘合剂选自纤维素衍生物、藻酸盐、明胶或聚乙烯吡咯烷酮等;
所述崩解剂选自微晶纤维素、羧甲基淀粉钠、聚乙烯吡咯烷酮、低取代羟丙基纤维素或交联羧甲基纤维素钠;
所述润滑剂选自硬脂酸、聚乙二醇、碳酸钙、碳酸氢钠、二氧化硅、滑石粉或硬脂酸镁;
所述表面活性剂选自十二烷基苯磺酸钠、硬脂酸、聚氧乙烯-聚氧丙烯共聚物、脂肪酸山梨坦或聚山梨酯(吐温)等;
所述矫味剂选自阿斯巴甜、蔗糖素或糖精钠。
本发明提供的治疗鼻炎的药物组合物具有以下优点:
本发明通过药效学试验资料显示治疗鼻炎270例,总有效率达94.82%,效果明显,并且未发现不良反应与毒副作用,说明本发明药物组合物治疗鼻炎疗效显著,具有良好推广价值。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1
组方:风毛菊20g、黑冰片5g、九香虫10g、石吊兰10g、白芷10g、两头尖20g、连钱草15g、细辛5g、鸡冠花10g、甘草10g。
制备方法:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮3次,每次2小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入2倍量的75%的乙醇,浸泡13小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加4倍量的水,煎煮3次,每次0.5小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入占混合均匀细粉重量1/5的淀粉,装入胶囊,制成胶囊剂。
实施例2
组方:风毛菊70g、黑冰片30g、九香虫60g、石吊兰60g、白芷60g、两头尖65g、连钱草65g、细辛40g、鸡冠花60g、甘草60g。
制备方法:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮6次,每次4小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入4倍量的90%的乙醇,浸泡18小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加6倍量的水,煎煮5次,每次2小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入占混合均匀细粉重量1/5的淀粉,装入胶囊,制成胶囊剂。
实施例3
组方:风毛菊25g、黑冰片8g、九香虫15g、石吊兰15g、白芷15g、两头尖25g、连钱草20g、细辛10g、鸡冠花15g、甘草15g。
制备方法:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮4次,每次3小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入3倍量的85%的乙醇,浸泡14小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加5倍量的水,煎煮4次,每次1小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入占混合均匀细粉重量1/5的淀粉,干燥,压片,即得本申请的片剂。
实施例4
组方:风毛菊65g、黑冰片28g、九香虫55g、石吊兰55g、白芷55g、两头尖60g、连钱草60g、细辛30g、鸡冠花55g、甘草55g。
制备方法:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮3-6次,每次2-4小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入2-4倍量的75-90%的乙醇,浸泡13-18小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加4-6倍量的水,煎煮3-5次,每次0.5-2小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入占混合均匀细粉重量1/5的淀粉,干燥,压片,即得本申请的片剂。
实施例5
组方:风毛菊30g、黑冰片10g、九香虫20g、石吊兰20g、白芷20g、两头尖30g、连钱草30g、细辛15g、鸡冠花20g、甘草20g。
制备方法:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮5次,每次3小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入3倍量的75%的乙醇,浸泡15小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加5倍量的水,煎煮4次,每次1小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
实施例6
组方:风毛菊60g、黑冰片25g、九香虫50g、石吊兰50g、白芷50g、两头尖50g、连钱草50g、细辛25g、鸡冠花50g、甘草50g。
制备方法:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮5次,每次3小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入3倍量的75%的乙醇,浸泡15小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加5倍量的水,煎煮4次,每次1小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
实施例7
组方:风毛菊35g、黑冰片12g、九香虫25g、石吊兰25g、白芷25g、两头尖35g、连钱草35g、细辛17g、鸡冠花25g、甘草25g。
制备方法:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮5次,每次3小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入3倍量的75%的乙醇,浸泡15小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加5倍量的水,煎煮4次,每次1小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
实施例8
组方:风毛菊55g、黑冰片22g、九香虫45g、石吊兰45g、白芷45g、两头尖45g、连钱草45g、细辛22g、鸡冠花45g、甘草45g。
制备方法:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮5次,每次3小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入3倍量的75%的乙醇,浸泡15小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加5倍量的水,煎煮4次,每次1小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
实施例9
组方:风毛菊40g、黑冰片20g、九香虫35g、石吊兰35g、白芷35g、两头尖40g、连钱草40g、细辛20g、鸡冠花35g、甘草35g。
制备方法:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮5次,每次3小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入3倍量的75%的乙醇,浸泡15小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加5倍量的水,煎煮4次,每次1小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入占混合均匀细粉重量1/5的淀粉,装入胶囊,制成胶囊剂。
为了进一步简述本发明的有益效果,发明人做了临床试验,具体如下:
1、病例来源
在6个医院随机选取270名鼻炎患者进行实验,分成9组,各组之间无显著性差异,年龄25~62岁,临床症状:鼻黏膜肿胀,分泌物增多,鼻塞,打喷嚏,鼻痒。
2、治疗方法
使用上述制得的实施例1-9药物组合物,口服,一次4g,一天3次,观察疗效。
3、疗效标准
疗效评定标准:疗效评定标准参照《中医药新药临床研究指导原则》制定:治愈:临床症状体征消失;
显效:临床症状体征基本或大部分消失;
有效:临床症状体征有减轻或缓解;
无效:临床症状体征无改善。
4、实验结果
绝大部分患者在按照本发明方法使用药物10天左右症状减轻,服用20天后,结果见表1:
表1疗效统计表
组别 | 临床痊愈 | 显效 | 有效 | 无效 | 合计 | 有效率(%) |
实施例1 | 12 | 8 | 9 | 1 | 30 | 96.7% |
实施例2 | 13 | 9 | 6 | 2 | 30 | 93.3% |
实施例3 | 15 | 5 | 9 | 1 | 30 | 96.7% |
实施例4 | 14 | 7 | 7 | 2 | 30 | 93.3% |
实施例5 | 13 | 6 | 10 | 1 | 30 | 96.7% |
实施例6 | 12 | 6 | 11 | 1 | 30 | 96.7% |
实施例7 | 13 | 6 | 9 | 2 | 30 | 93.3% |
实施例8 | 9 | 8 | 12 | 1 | 30 | 96.7% |
实施例9 | 11 | 8 | 8 | 3 | 30 | 90.0% |
治疗鼻炎270例,总有效率达94.82%,效果明显,并且未发现不良反应与毒副作用,说明本发明药物组合物治疗鼻炎疗效显著,具有良好推广价值。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作出一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (10)
1.一种治疗鼻炎的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:风毛菊20-70份、黑冰片5-30份、九香虫10-60份、石吊兰10-60份、白芷10-60份、两头尖20-65份、连钱草15-65份、细辛5-40份、鸡冠花10-60份、甘草10-60份。
2.根据权利要求1所述的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:风毛菊25-65份、黑冰片8-28份、九香虫15-55份、石吊兰15-55份、白芷15-55份、两头尖25-60份、连钱草20-60份、细辛10-30份、鸡冠花15-55份、甘草15-55份。
3.根据权利要求2所述的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:风毛菊30-60份、黑冰片10-25份、九香虫20-50份、石吊兰20-50份、白芷20-50份、两头尖30-50份、连钱草30-50份、细辛15-25份、鸡冠花20-50份、甘草20-50份。
4.根据权利要求3所述的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:风毛菊35-55份、黑冰片12-22份、九香虫25-45份、石吊兰25-45份、白芷25-45份、两头尖35-45份、连钱草35-45份、细辛17-22份、鸡冠花25-45份、甘草25-45份。
5.根据权利要求4所述的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:风毛菊40份、黑冰片20份、九香虫35份、石吊兰35份、白芷35份、两头尖40份、连钱草40份、细辛20份、鸡冠花35份、甘草35份。
6.根据权利要求1-5任一项所述的药物组合物,其特征在于,该药物组合物还含有药学上可接受的载体或稀释剂。
7.根据权利要求6所述的药物组合物,其特征在于,所述药物组合物为固体制剂或液体制剂,所述固体制剂为片剂、胶囊剂、颗粒剂或丸剂;所述液体制剂为口服液。
8.一种制备权利要求1-5任一项所述的药物组合物的方法,其特征在于,该方法包括以下步骤:
将风毛菊、黑冰片、九香虫、石吊兰、白芷、两头尖、连钱草、细辛、鸡冠花、甘草粉碎过筛,与药学上可接受的载体或稀释剂混合均匀,制备成制剂。
9.一种制备权利要求1-5任一项所述药物组合物的方法,其特征在于,该方法包括以下步骤:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮3-6次,每次2-4小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入2-4倍量的75-90%的乙醇,浸泡13-18小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加4-6倍量的水,煎煮3-5次,每次0.5-2小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入药学上可接受的载体或稀释剂混合均匀,制成制剂。
10.根据权利要求9所述药物组合物的制备方法,其特征在于,该方法包括以下步骤:
1)称取重量份药物;
2)将白芷、两头尖、连钱草、细辛、鸡冠花、甘草加水煎煮5次,每次3小时,合并煎液,滤过,滤液浓缩干燥,粉碎成细粉,备用;
3)将风毛菊、黑冰片、九香虫、石吊兰加入3倍量的75%的乙醇,浸泡15小时,过滤,滤液浓缩,干燥,粉碎成细粉备用;滤渣加5倍量的水,煎煮4次,每次1小时,滤过,合并滤液,浓缩干燥,粉碎成细粉,备用;
4)将步骤2)、3)备用的细粉混合均匀,加入药学上可接受的载体或稀释剂混合均匀,制成制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610402881.9A CN105902630A (zh) | 2016-06-03 | 2016-06-03 | 一种治疗鼻炎的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610402881.9A CN105902630A (zh) | 2016-06-03 | 2016-06-03 | 一种治疗鼻炎的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105902630A true CN105902630A (zh) | 2016-08-31 |
Family
ID=56750928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610402881.9A Pending CN105902630A (zh) | 2016-06-03 | 2016-06-03 | 一种治疗鼻炎的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105902630A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102225116A (zh) * | 2011-06-02 | 2011-10-26 | 长治市郊区黄碾镇中心卫生院 | 一种治疗鼻炎的药物及其制备方法 |
CN102274334A (zh) * | 2011-09-13 | 2011-12-14 | 潞城市九鼎保健品有限公司 | 一种治疗鼻炎的药物及其制备方法 |
CN102441034A (zh) * | 2010-10-09 | 2012-05-09 | 田荣春 | 一种治疗过敏性鼻炎的药物 |
CN103948680A (zh) * | 2014-04-12 | 2014-07-30 | 姜义祥 | 一种治疗肺寒型鼻炎的鼻炎栓及其制备方法 |
-
2016
- 2016-06-03 CN CN201610402881.9A patent/CN105902630A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102441034A (zh) * | 2010-10-09 | 2012-05-09 | 田荣春 | 一种治疗过敏性鼻炎的药物 |
CN102225116A (zh) * | 2011-06-02 | 2011-10-26 | 长治市郊区黄碾镇中心卫生院 | 一种治疗鼻炎的药物及其制备方法 |
CN102274334A (zh) * | 2011-09-13 | 2011-12-14 | 潞城市九鼎保健品有限公司 | 一种治疗鼻炎的药物及其制备方法 |
CN103948680A (zh) * | 2014-04-12 | 2014-07-30 | 姜义祥 | 一种治疗肺寒型鼻炎的鼻炎栓及其制备方法 |
Non-Patent Citations (5)
Title |
---|
南京中医药大学编著: "《中药大辞典》", 31 March 2006 * |
国家中医药管理局《中华本草》编委会编著: "《中华本草.蒙药卷》", 30 September 2004 * |
夏华玲等主编: "《常用中药材薄层鉴别方法》", 30 April 2015, 郑州大学出版社 * |
江山著: "《老名方治常见病》", 31 March 2016, 中医古籍出版社 * |
高松主编: "《辽宁中药志》", 31 December 2010, 辽宁科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08295632A (ja) | 抗菌剤 | |
CN103830632A (zh) | 一种根治银屑病等多种皮肤病的中药制剂及其制备方法与应用 | |
CN104225006A (zh) | 一种益气通便的中药组合物 | |
CN102755361A (zh) | 一种用于防治鼻炎的湿巾及其制备方法 | |
WO2022160520A1 (zh) | 一种治疗颈椎间盘突出的药物组合物及其制备方法和应用 | |
CN100356944C (zh) | 一种具有止咳平喘功能的药物 | |
CN105853920A (zh) | 一种治疗产后病的中药组合物及其制备方法 | |
CN112107609A (zh) | 金骨莲制剂在制备治疗睑板腺囊肿药物中的应用 | |
CN101744906B (zh) | 一种中药组合物在制备治疗面神经麻痹药物中的应用 | |
CN105902630A (zh) | 一种治疗鼻炎的药物组合物及其制备方法 | |
CN104510854B (zh) | 一种治疗妇女痛经的中药组合物及其用途 | |
CN103961455A (zh) | 一种清热解毒的中药复方制剂及其制备方法 | |
CN1907335A (zh) | 一种用于治疗鼻渊的药物组合物及其制备方法 | |
CN101028490A (zh) | 一种治疗痤疮的中成药 | |
CN105709077A (zh) | 一种治疗产后病的中药组合物及其制备方法 | |
JP4933000B2 (ja) | 抗ヘリコバクター・ピロリ薬 | |
CN105770828A (zh) | 一种治疗内分泌失调的中药组合物及其制备方法 | |
CN103948899A (zh) | 一种治疗萎缩性胃炎的藏药 | |
CN104225034B (zh) | 一种组合物在制备治疗非感染性尿道综合症药物中的应用 | |
CN104258113B (zh) | 一种治疗脑出血的中药组合物 | |
CN105816519A (zh) | 一种治疗肺气肿的药物组合物及其制备方法 | |
CN106266705A (zh) | 一种治疗痛风的药物组合物 | |
CN108938785B (zh) | 一种治疗咳嗽变异性哮喘的中药组合物及其制备方法 | |
CN101693058B (zh) | 一种用于预防和治疗感冒及炎症感染的药物 | |
CN105687730B (zh) | 一种用于局部止痛的复方延胡索中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160831 |
|
RJ01 | Rejection of invention patent application after publication |